Business context and reporting period
Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing small-molecule therapies for age-related degenerative diseases of the central nervous system and retina. Its lead candidate, CT1812, targets the sigma-2 receptor complex and is being studied in Alzheimer’s disease (AD) and dementia with Lewy bodies (DLB), with development planned for geographic atrophy secondary to dry age-related macular degeneration (dry AMD).
This Form 10-K covers the fiscal year ended December 31, 2022, with 2021 as the comparable year; it does not provide standalone fourth-quarter results. The company had no approved products and no product-sale revenue.
Financial and operating metrics
| Metric | FY 2022 | FY 2021 |
|---|---|---|
| Product revenue | None | None |
| Grant income | $22.2 million | $17.4 million |
| Research and development expense | $30.3 million | $18.6 million |
| General and administrative expense | $13.2 million | $10.0 million |
| Net loss | $21.4 million | $11.7 million |
| Net loss per share, basic and diluted | $0.91 | $3.13 |
| Cash used in operating activities | $18.5 million | $3.6 million |
| Cash and cash equivalents at year-end | $41.6 million | $54.7 million |
| Total assets | $50.4 million | $59.1 million |
| Total liabilities | $10.2 million | $7.9 million |
| Stockholders’ equity | $40.2 million | $51.3 million |
Operating margin is not meaningful because the company had no product revenue. Grant income is reported as other income, not product revenue. Current assets were $47.6 million and current liabilities were $7.8 million at year-end. The filing reports $0.6 million outstanding on an insurance-premium financing arrangement; it reports no material litigation contingency.
Material changes versus the prior comparable period
- Net loss increased $9.7 million, while operating expenses rose $15.0 million. R&D expense increased mainly with Phase 2 trial activity; G&A expense increased with professional fees, insurance, and headcount.
- Operating cash use increased $14.9 million. Cash declined $13.2 million during 2022, compared with a $49.5 million increase in 2021, when the company received IPO and SAFE proceeds.
- Grant income increased $4.8 million, reflecting higher eligible reimbursable costs. The company reported approximately $171 million in cumulative grants awarded, primarily from the National Institute on Aging (NIA).
- The November 2022 follow-on offering raised approximately $5.2 million net from 5.0 million shares at $1.20 per share. No shares were sold under the $40 million at-the-market program during 2022.
- 2021 results included a $2.2 million gain from a derivative-liability fair-value change, a $2.2 million SAFE fair-value loss, and $0.4 million of PPP loan forgiveness income; these items did not recur in 2022. 2021 common-stockholder loss also included $4.5 million of preferred dividends.
Outlook, management commentary, risks and unusual items
- Management estimated that year-end cash, cash equivalents, and income from non-dilutive grants would fund operating and capital requirements into the second half of 2024, assuming no use of the ATM or the later Lincoln Park facility. The company expects to need substantial additional capital and cannot fund all candidates through approval from current resources.
- CT1812 remained in Phase 2 development. In the SHINE trial, an interim analysis of the first 24 patients showed a biomarker difference and a numerical approximately three-point ADAS-Cog 11 treatment difference versus placebo; the cognitive difference was not statistically significant (p=0.1295). The company cautioned that the interim analysis was not powered to detect significant treatment differences. Enrollment was expected to complete in 2023, with topline data expected in 2024.
- The 540-patient START Phase 2 trial in early-stage AD was planned to open sites in the first half of 2023 and is supported by an approximately $81 million NIA grant. The 120-patient DLB Phase 2 trial was recruiting. The FDA cleared the dry-AMD IND in January 2023; the company planned to initiate the MAGNIFY Phase 2 trial in 2023.
- Management stated that CT1812 had generally been well tolerated in trials to date, but reported mild, transient liver-enzyme elevations in some participants. Early-stage and interim clinical findings are uncertain and may not predict later trial outcomes.
- Key risks include dependence on CT1812, clinical and regulatory failure or delay, patient enrollment, reliance on third-party trial operators and manufacturers, need for financing, possible dilution, grant eligibility and audit risk, competition, intellectual-property challenges, and uncertain future coverage and pricing. The company has no commercial sales infrastructure and relies on third parties for manufacturing.
- Subsequent financing developments included an effective $200 million shelf registration, a $40 million ATM program, and a March 2023 agreement allowing up to $35 million of share purchases by Lincoln Park, subject to conditions. The company issued 189,856 commitment shares under that agreement. These facilities may provide capital but could dilute shareholders.
- The filing reports effective disclosure controls and internal control over financial reporting as of December 31, 2022. Ernst & Young LLP gave an unqualified opinion on the financial statements; it did not audit internal control effectiveness.
Most important facts for investors to verify
- Current cash runway and actual grant reimbursements versus management’s estimate through the second half of 2024; confirm assumptions and subsequent financing draws.
- Final, adequately powered SHINE results and subsequent data from SEQUEL, START, SHIMMER, and MAGNIFY, including safety, clinical endpoints, and statistical significance.
- Whether clinical-trial costs, enrollment, and timelines remain consistent with company plans and NIA grant conditions.
- Manufacturing capacity, supplier diversification, and the timing and cost of scale-up for any future trials or commercialization.
- Potential dilution from the ATM, Lincoln Park agreement, stock compensation, and future capital raises.
- Whether any grant audit, regulatory development, or newly identified safety issue changes the company’s financial outlook or CT1812 development plans.